Authors: Takashi Mizowaki Yoshiki Norihisa Kenji Takayama Itaru Ikeda Haruo Inokuchi Kiyonao Nakamura Tomomi Kamba Takahiro Inoue Toshiyuki Kamoto Osamu Ogawa Masahiro Hiraoka
Publish Date: 2016/02/03
Volume: 21, Issue: 4, Pages: 783-790
Abstract
Fifty patients with T1cT2N0M0 prostate cancer who were treated with highdose IMRT combined with neoadjuvant HT were evaluated Of these patients 19 and 31 were classified into the intermediate and highrisk groups respectively Neoadjuvant HT was administered over a median duration of 6 months 74 and 78 Gy in 2 Gy per fraction were essentially delivered to the intermediate and highrisk cases respectively Adjuvant HT was not administered to any of the patients after the completion of IMRTOver a median followup period of 118 months the 10year prostatespecific antigen failurefree survival prostatespecific antigen failurefree salvage hormonal therapyfree prostate cancerspecific survival and overall survival rates were 702 787 892 100 and 888 respectively No grade 3 or higher acute or late toxicities were observed The 10year likelihoods of developing grade 2 late urinary and rectal toxicities were 137 and 42 respectively Compared with the outcomes of a cohort of historical controls who were locally irradiated with 70 Gy by threedimensional conformal radiotherapy the prostatespecific antigen failurefree rate was significantly better in the IMRT groups 787 vs 534 at 10 years p = 0027Highdose IMRT combined with neoadjuvant HT achieved not only high prostatespecific antigen control but also excellent survival outcomes with acceptable morbidities for a Japanese cohort of intermediate and highrisk T1cT2N0M0 prostate cancer patients and these results warrant further investigationThis work was supported in part by GrantsinAid for scientific research from the Ministry of Education Culture Sports Science and Technology 24591838 Japan and New Energy and Industrial Technology Development Organization NEDO The funding programs had no effects on the study design or interpretation of data
Keywords: